3-碘-2-硝基苯酚 | 861010-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-碘-2-硝基苯酚
• 英文名称: 3-iodo-2-nitro-phenol
• 英文别名: 3-Jod-2-nitro-1-hydroxy-benzol；3-Jod-2-nitro-phenol；3-iodonitrophenol；3-Iodo-2-nitrophenol
• CAS: 861010-57-3
• 化学式: C₆H₄INO₃
• 分子量: 265.007
• InChiKey: DVEGEGXFFSZLBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-碘-2-硝基苯酚 在 硫酸 、 硝酸 作用下， 生成 3-iodo-2,4,6-trinitro-phenol
  参考文献：
  名称：

  Hodgson; Moore, Journal of the Chemical Society, 1927, p. 634

  摘要：

  DOI：
• 作为产物：
  描述：

  3-碘苯酚 在 硫酸 作用下， 生成 3-碘-2-硝基苯酚
  参考文献：
  名称：

  Hodgson; Moore, Journal of the Chemical Society, 1927, p. 634

  摘要：

  DOI：

文献信息

• 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
  申请人：SmithKline Beecham Corporation

  公开号：US05861421A1

  公开（公告）日：1999-01-19

  This invention relates to derivatives of 4,4-(disubstituted)cyclohexan-1-ones and related compounds which are useful for treating allergic and inflammatory diseases.

  这项发明涉及4,4-(二取代)环己烷-1-酮及相关化合物的衍生物，这些化合物对治疗过敏和炎症性疾病有用。
• Microporous Semicrystalline Silica Materials
  作者：Man Park、Sridhar Komarneni、W. T. Lim、N. H. Heo、J. Choi

  DOI：10.1557/jmr.2000.0208

  日期：2000.7

  A new family of microporous semicrystalline silica materials (MSSMs) were developed at room temperature from acidic mixtures of alkyl-substituted silane and tetramethylalkoxysilane. Hydrolyzed alkyl-substituted silica precursors, having hydrophilic silanol groups and hydrophobic alkyl groups, presumably act not only as templates but also as sol stabilizers for continuous pore engineering of silica materials in the micropore region. Depending on the substituted alkyl (SUA) groups in initial sols, MSSMs have distinct broad x-ray diffraction peaks in low 2θ range of 2° to 12°, distinguishable thermal behavior of SUA groups, highly flexible processability, and discrete micropore size with good thermal stability of micropores after the removal of SUA groups. These designer microporous silicas are expected to be useful for molecular sieving applications.

  利用烷基取代硅烷和四甲基烷氧基硅烷的酸性混合物在室温下开发出了一系列新型微孔半结晶二氧化硅材料（MSSM）。水解的烷基取代二氧化硅前体具有亲水性硅烷醇基团和疏水性烷基基团，不仅可以作为模板，还可以作为溶胶稳定剂，用于二氧化硅材料在微孔区域的连续孔隙工程。根据初始溶胶中取代的烷基（SUA）基团的不同，MSSM 在 2° 至 12° 的低 2θ 范围内具有不同的宽 X 射线衍射峰，SUA 基团的热行为不同，具有高度灵活的可加工性，微孔尺寸离散，去除 SUA 基团后微孔具有良好的热稳定性。这些设计型微孔硅有望用于分子筛分应用。
• Immunoconjugates and prodrugs and their use in association for drug delivery
  申请人：CELLTECH LIMITED

  公开号：EP0392745A2

  公开（公告）日：1990-10-17

  A drug delivery system is described in which an immunoconjugate and a prodrug are used in association with each other to deliver a drug to a host target site such as a tumour. The immunoconjugate comprises an antibody or antibody fragment to which is attached a β-lactamase or an active fragment thereof. The prodrug is a cyclic amide derivative of a drug or an unstable precursor thereof in which the drug or precusor is attached to the remainder of the prodrug such that it forms a leaving group which on hydrolysis of the prodrug is eliminated as the active drug or unstable precursor. Particular prodrugs include penicillin or cephalasporin derivatives and other β-lactams to which are attached any physiologically active substances, particularly antineoplastic agents, antiviral, antibacterial or antifungal compounds. In use the immunoconjugate is adminstered first such that it localises at the host target site. Subsequent administration of the prodrug results in β-lactamase catalysed hydrolysis of the prodrug at the target site with release of the active drug or unstable precursor.

  本文描述了一种给药系统，其中免疫共轭物和原药相互结合使用，将药物输送到宿主的靶点，如肿瘤。免疫结合剂由抗体或抗体片段组成，抗体或抗体片段上附有β-内酰胺酶或其活性片段。原药是药物或其不稳定前体的环状酰胺衍生物，其中药物或前体与原药的其余部分相连，从而形成一个离去基团，该离去基团在原药水解时作为活性药物或不稳定前体被消除。特别的原药包括青霉素或头孢菌素衍生物和其他 β-内酰胺类，这些物质上附有任何生理活性物质，特别是抗肿瘤剂、抗病毒、抗菌或抗真菌化合物。在使用过程中，首先对免疫结合剂进行给药，使其在宿主靶点定位。随后给药，原药在β-内酰胺酶催化下在靶点水解，释放出活性药物或不稳定的前体。
• METHODS FOR APOLIPOPROTEIN DETECTION
  申请人：Biocross, S.L.

  公开号：EP3163303A1

  公开（公告）日：2017-05-03

  The present invention relates to methods for the detection and quantification of apolipoproteins and isoforms thereof in a sample, as well as to predictive methods of the probability of neurodegenerative or cardiovascular disease development based on apolipoprotein levels as determined by the detection methods of the invention.

  本发明涉及检测和量化样本中脂蛋白及其异构体的方法，以及根据本发明检测方法确定的脂蛋白水平预测神经退行性疾病或心血管疾病发病概率的方法。
• FPR2 RECEPTOR AGONIST APTAMERS AND USES THEREOF
  申请人：Universidad Carlos III de Madrid

  公开号：EP3981878A1

  公开（公告）日：2022-04-13

  The present invention is related to FPR2 receptor agonist aptamers and uses thereof. The present invention is related to a nucleic acid aptamer that is able to specifically bind to the FPR2 receptor and activate said FPR2 receptor, comprising a nucleotide sequence with a sequence identity of at least 70% with the sequence SEQ ID NO. 1, SEQ ID NO. 2 or SEQ ID NO. 3.

  本发明涉及 FPR2 受体激动剂适配体及其用途。本发明涉及一种能与 FPR2 受体特异性结合并激活所述 FPR2 受体的核酸适配体，该适配体包含与 SEQ ID NO.1、SEQ ID NO.2 或 SEQ ID NO.3 序列具有至少 70% 序列同一性的核苷酸序列。